文献速递核素与放射性配体治疗

在177Lu-lilotomab satetraxetan治疗前预给予lilotomab可显著提高非霍奇金淋巴瘤患者肿瘤与红骨髓吸收剂量之比

Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-22

本研究为首次人体1/2a期研究,共19例复发CD37阳性惰性非霍奇金淋巴瘤患者、47个病灶纳入剂量学分析,比较四个不同预给药/预处理方案组的肿瘤与正常组织吸收剂量。结果显示红骨髓是剂量限制器官,预给予lilotomab可降低红骨髓吸收剂量并显著提高肿瘤与红骨髓吸收剂量比值。

要点

  • 红骨髓是177Lu-lilotomab satetraxetan治疗的剂量限制器官。
  • 预给予lilotomab可降低红骨髓吸收剂量,提高肿瘤与红骨髓吸收剂量比值。
  • lilotomab从40 mg增至100 mg/m2可轻度降低红骨髓吸收剂量并提高肿瘤与红骨髓比值。

核心结论

  • 红骨髓是177Lu-lilotomab satetraxetan治疗的主要剂量限制器官,预给予lilotomab对红骨髓吸收剂量有减轻作用。
  • lilotomab从40 mg增至100 mg/m2可轻度降低红骨髓吸收剂量并提高肿瘤与红骨髓吸收剂量比值。
  • 两种预给予剂量均使肿瘤与红骨髓吸收剂量比值显著高于未预给予组。
  • 研究结果鼓励继续使用lilotomab预给予。

研究设计与样本

  • 首次人体1/2a期研究,纳入复发CD37阳性惰性非霍奇金淋巴瘤患者,四个不同预给药和预处理组合组。
  • 19例患者纳入剂量学分析,共47个病灶。
  • 第1组和第4组分别预给予冷lilotomab 40 mg固定剂量和100 mg/m2体表面积剂量,第2组和第3组未预给予lilotomab。
  • 所有患者均接受不同方案的利妥昔单抗预处理。
  • 患者接受177Lu-lilotomab satetraxetan 10、15或20 MBq/kg体重。

主要发现

  • 除肿瘤外,红骨髓、肝脏、脾脏和肾脏对177Lu-lilotomab satetraxetan有 distinct 摄取。
  • 第1-4组平均红骨髓吸收剂量分别为0.94、1.55、1.44和0.89 mGy/MBq。
  • 未预给予lilotomab组(第2组和第3组合并)平均红骨髓吸收剂量为1.48 mGy/MBq,显著高于第1组(p=0.04)和第4组(p=0.02)。
  • 第4组脾脏吸收剂量显著低于未预给予lilotomab组(1.13 vs. 3.20 mGy/MBq;p<0.01)。
  • 第1-4组平均肿瘤吸收剂量分别为2.15、2.31、1.33和2.67 mGy/MBq。

关键数值与推荐

  • 第1组和第4组分别预给予冷lilotomab 40 mg固定剂量和100 mg/m2体表面积剂量。
  • 177Lu-lilotomab satetraxetan给药活度为10、15或20 MBq/kg体重。
  • 未预给予lilotomab组平均红骨髓吸收剂量1.48 mGy/MBq显著高于第1组(p=0.04)和第4组(p=0.02)。
  • 第4组脾脏吸收剂量1.13 mGy/MBq显著低于未预给予组3.20 mGy/MBq(p<0.01)。
  • 第1组和第4组肿瘤与红骨髓吸收剂量比值分别为2.16和4.62,均显著高于未预给予组1.07(p=0.05和p=0.02)。

临床怎么用

  • 原文结论鼓励继续使用lilotomab预给予,但未给出具体临床推荐等级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 177Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been investigated in a first-in-human phase 1/2a study for relapsed CD37+ indolent NHL. The aim of this work was to determine the tumor and normal tissue absorbed doses for all four arms, and investigate possible variations in the ratios of tumor to organs-at-risk absorbed doses. METHODS: Two of the phase 1 arms included cold lilotomab pre-dosing (arm 1 and 4; 40 mg fixed and 100 mg/m2 BSA dosage, respectively) and two did not (arms 2 and 3). All patients were pre-treated with different regimens of rituximab. The patients received either 10, 15, or 20 MBq 177Lu-lilotomab satetraxetan per kg body weight. Nineteen patients were included for dosimetry, and a total of 47 lesions were included. The absorbed doses were calculated from multiple SPECT/CT-images and normalized by administered activity for each patient. Two-sided Student's t tests were used for all statistical analyses. RESULTS: Organs with distinct uptake of 177Lu-lilotomab satetraxetan, in addition to tumors, were red marrow (RM), liver, spleen, and kidneys. The mean RM absorbed doses were 0.94, 1.55, 1.44, and 0.89 mGy/MBq for arms 1-4, respectively. For the patients not pre-dosed with lilotomab (arms 2 and 3 combined) the mean RM absorbed dose was 1.48 mGy/MBq, which was significantly higher than for both arm 1 (p = 0.04) and arm 4 (p = 0.02). Of the other organs, the highest uptake was found in the spleen, and there was a significantly lower spleen absorbed dose for arm-4 patients than for the patient group without lilotomab pre-dosing (1.13 vs. 3.20 mGy/MBq; p < 0.01). Mean tumor absorbed doses were 2.15, 2.31, 1.33, and 2.67 mGy/MBq for arms 1-4, respectively. After averaging the tumor absorbed dose for each patient, the patient mean tumor absorbed dose to RM absorbed dose ratios were obtained, given mean values of 1.07 for the patient group not pre-dosed with lilotomab, of 2.16 for arm 1, and of 4.62 for arm 4. The ratios were significantly higher in both arms 1 and 4 compared to the group without pre-dosing (p = 0.05 and p = 0.02). No statistically significant difference between arms 1 and 4 was found. CONCLUSIONS: RM is the primary dose-limiting organ for 177Lu-lilotomab satetraxetan treatment, and pre-dosing with lilotomab has a mitigating effect on RM absorbed dose. Increasing the amount of lilotomab from 40 mg to 100 mg/m2 was found to slightly decrease the RM absorbed dose and increase the ratio of tumor to RM absorbed dose. Still, both pre-dosing amounts resulted in significantly higher tumor to RM absorbed dose ratios. The findings encourage continued use of pre-dosing with lilotomab.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Stokke C, Blakkisrud J, Løndalen A, et al. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging. 2018. PMID: 29470615. doi:10.1007/s00259-018-3964-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。